Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X)
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase II MATCH treatment trial identifies the effects of dasatinib in patients whose
cancer has a genetic change called DDR2 mutation. Dasatinib may block proteins called
tyrosine kinases, which may be needed for cancer cell growth. Researchers hope to learn if
dasatinib will shrink this type of cancer or stop its growth.